Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 20 Show results per page	View Search Criteria \| Help With Results


1.		PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				20040249 NCT00115765

Last Modified: 6/8/2007 First Published: 8/6/2006


2.		Phase III Randomized Study of Prophylactic Topical Sunscreen for the Prevention of Erlotinib-, Cetuximab-, or Other Epidermal Growth Factor Receptor Inhibitor-Induced Skin Rash in Patients With Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				18 and over				NCI				NCCTG-N05C4 N05C4, NCCTG N05C4, NCT00362986


3.		Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				20050181 NCT00339183


4.		PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				20050203 NCT00364013

Last Modified: 9/10/2003 First Published: 6/1/2002


5.		Phase II Study of Monoclonal Antibody ABX-EGF in Patients With Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0112063 IMMUNEX-054-0005, NCI-G02-2073, NCT00039273

Last Modified: 6/8/2004 First Published: 10/1/2002


6.		Phase II Study of Monoclonal Antibody ABX-EGF, Irinotecan, Leucovorin Calcium, and Fluorouracil in Patients With Metastatic Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0203073 IMMUNEX-054.0009, NCI-G02-2115, NCT00047151

Last Modified: 6/8/2004 First Published: 1/26/2003


7.		Phase II Study of Monoclonal Antibody ABX-EGF in Patients With Hormone-Resistant Prostate Cancer With Elevated PSA Levels Without Metastasis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0206074 ABX-0301, NCT00054574

Last Modified: 3/6/2008 First Published: 8/24/2003


8.		Phase II Randomized Study of Monoclonal Antibody ABX-EGF, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0304051 IMMUNEX-054.0004, ABX-0304, AMGEN-20025404, NCT00034346


9.		ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				ABX-0310 ABX-EGF, NCT00061126

Last Modified: 4/26/2005 First Published: 2/20/2004


10.		Phase II Study of Monoclonal Antibody ABX-EGF as Second-Line Treatment for Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0308088 IMMUNEX-054.0008, AMGEN-20025408, ABX-0308, NCT00079209

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute